Stockreport

NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024 [Yahoo! Finance]

NeuroSense Therapeutics Ltd.  (NRSN) 
PDF It is incurable and results in complete paralysis and ultimately death within two to five years from diagnosis. Each year, about 5,000 people in the U.S. are diagnosed w [Read more]